Late-stage pipeline products have the potential to change how type 2 diabetes is treated today, says GBI Research. The business intelligence firm forecasts that the Southeast Asian type 2 diabetes mellitus
(T2DM) market, covering South Korea, Singapore, Taiwan, Malaysia, the
Philippines, Thailand, Vietnam and Indonesia, will rise from US$1.7
billion in 2015 to US$2.7 billion by 2022, at a CAGR of 7.1%.
Aswini Nath, Analyst for GBI Research, explains: “Unmet needs relating
to patient convenience and ease of use will be addressed significantly
over the forecast period. Higher levels of innovation are apparent in
the early-stage pipeline, which may lead to considerable improvements
beyond the existing range of products, in terms of safety and efficacy
in the long term.
“In terms of recently approved therapeutics, GLP-1 receptor agonists,
DPP-4 inhibitors, and SGLT-2 inhibitors* have already achieved strong
market uptake and are all expected to increase their market shares over
the forecast period. In comparison with many previously marketed
therapies, these new products provide improved weight control and
lowered hypoglycemia risk.”
The company named Novo Nordisk’s NN-9535
(semaglutide subcutaneous formulation) and OG-217SC (semaglutide oral
formulation) and Eli Lilly’s Trulicity (dulaglutide), which are GLP-1
receptor agonists; as well as Merck’s ertugliflozin and Theracos's bexagliflozin,
which are SGLT-2 inhibitors; and Merck’s omarigliptin, which is a DPP-4
inhibitor, as products close to commercialisation which "stand out as offering superior
safety, efficacy, and patient compliance".
Of these products, GBI Research believes that OG-217SC, being a
first-to-market oral formulation in the GLP-1 agonist class of drug, has
the most potential to change the treatment paradigm due to its improved
administration route compared to other drugs in the same class.
However, Nath added that popular treatment metformin (Glucophage) will continue to dominate treatment options. “Although increased uptake of branded drugs is expected, metformin – a low-cost generic drug – will maintain its pivotal role in the T2DM treatment algorithm in Southeast Asia. Due to its well-characterised safety and efficacy profiles, wide availability and low cost, metformin will continue to be prescribed as the first-line pharmacotherapy and also remain the favored option for use in combination therapies,” he said.
Interested?
Buy Type 2 Diabetes Mellitus Therapeutics in South-East Asia Markets to 2022 – Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
*GLP-1 stands for glucagon-like peptide-1 and DPP-4 is short for dipeptidyl peptidase 4. Both GLP-1 receptor agonists improve glycemic control while reducing body weight while DPP-4 improves glycemic control. Both also improve systolic blood pressure in patients
with type 2 diabetes. Read more about GLP-1 receptor agonists in Diabetes Care.
SGLT-2 or sodium-glucose linked transporter refers to the SGLT for the proximal convoluted tubule, a part of the kidney system, as opposed to SGLT-1, which affects the proximal straight tubule. Read more about SGLT-2 inhibitors in Diabetes Care.
